Listening to the Patient Voice: The Antidepressant Withdrawal Experience
Patient advocates join with researchers and service users to present first-hand experiences of antidepressant withdrawal.
Literally Indescribable: Are Antidepressants Addictive?
“My life was very, very good.” That’s how Michael sums up how things were for him—prior to his suffering from devastating withdrawal effects after discontinuing GlaxoSmithKline’s blockbuster drug Paxil.
New FDA Study Shows Benzodiazepines Can Cause Long-Term Injury
The FDA has finally acknowledged the adverse effects of benzodiazepines, the dangers of withdrawal, and that the current packaging does not sufficiently warn of these harms.
Suicide Rates Did Not Decrease When Antidepressant Drugs Were Introduced
Researchers investigate the claim that the introduction of antidepressant drugs led to decreases in suicide rates internationally.
A Short History of Tardive Dyskinesia: 65 Years of Drug-Induced Brain Damage That Rolls...
Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.
Increasing Numbers of Children Prescribed Multiple Psychiatric Medications
According to researchers, children are being increasingly prescribed multiple different psychiatric medications.
The Latest “Breakthrough Therapy”: Expensive New Drugs for Tardive Dyskinesia
The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.
Promising Preliminary Results from a Small Study of Psilocybin-Assisted Therapy
A new study offers promising results for psilocybin-assisted psychotherapy for depression.
Researchers: Antidepressant Use in Children Increases Suicide, No Evidence of Benefit
Noted antidepressant researcher, Michael Hengartner, summarizes the latest research on the use of antidepressants in children and adolescents.
Surviving Antidepressants: An Interview with Adele Framer
That is the truth about withdrawal syndrome: It’s like a 50-50 chance that you’re going to have a problem. If you’re in the unlucky half, you’re gonna be really unlucky.
Anticholinergic Drugs Increase Risk of Cognitive Decline
A new study finds that anticholinergic drugs, like antidepressants and antipsychotics, are associated with mild cognitive decline.
Researchers: It’s Time to Stop Recommending Antidepressants for Depression
Researchers review a new synthesis of the existing evidence and conclude that the harms of antidepressants outweigh any benefits.
Antipsychotic Augmentation Increases Risk of Death
A new study finds that adding an antipsychotic to existing antidepressant treatment is associated with a 45% increased risk of early death.
Greater Exposure to Antipsychotics Associated with Worse Long-Term Outcomes
A new study finds adverse long-term consequences associated with the increased use of antipsychotics in first-episode psychosis.
Psychiatry’s Top Experts Acknowledge Lasting Harms of Antidepressant Withdrawal
Royal College of Psychiatrists’ former president demands support for patients coming off antidepressants.
Further Results Confirm Antidepressants Increase Risk of Violent Crime By 26%
Taking an SSRI antidepressant was associated with a 26% increased risk of violent crime conviction.
Unblinding in Antidepressant Trials Biases Results
Studies that compare the effectiveness of different antidepressant drugs are unreliable, according to new research in BMC Psychiatry.
Stuart Shipko – SSRI Withdrawal: Shooting the Odds
We interview Dr. Stuart Shipko, a psychiatrist and author who has a particular interest in the side effects and withdrawal effects of SSRI antidepressants and the need for informed consent when prescribing.
Tapering Strips Help People Stop Using Antidepressants, Study Finds
A new study by Peter Groot and Jim van Os investigated whether tapering strips can help people stop using antidepressants.
Very Slow Taper Best for Antipsychotic Discontinuation
An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.
An FDA Whistleblower’s Documents: Commerce, Corruption, and Death
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.
Antipsychotics Associated with Severe COVID-19 and Fatal Outcomes
A new study has found a strong association between antipsychotic drugs and higher rates of severe cases of COVID-19.
Strategies for Tapering and Discontinuing Antidepressants
A new review of strategies to support both patients and practitioners through the process of discontinuing antidepressants.
Service-User Knowledge Helps Researchers Develop Psychiatric Drug Tapering Approaches
New strategies for tapering psychiatric drugs achieved by acknowledging withdrawal symptoms and valuing service-users’ first-hand knowledge.
For People “At Risk for Psychosis,” Antipsychotics Associated with Worse Outcomes
Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.
